Data from Pharmawand - Curated by EPG Health - Date added 14 June 2019

In the CARMELINA trial nearly 10% of all patients with diabetes had nephrotic-range proteinuria at baseline. This was associated with a high incidence of cardiovascular/kidney disease but this secondary disease burden could not be lowered by linagliptin. The antidiabetes drug reduced albuminuria and HbA1c in all patients, but did not affect the cardiovascular (CV) risk over 2.2 years. Additionally, it had no impact on the glomerular filtration rate (eGFR), a marker of kidney function. 

Diabetes mellitus is a significant and growing health problem which contributes significantly to the prevalence of chronic kidney disease (CKD). According to the ERAEDTA Registry, nearly a quarter (23%) of all patients who started renal replacement therapy in 2016 were patients with diabetes. The underlying idea of the study, which has been presented as a late breaking clinical trial at the ERA-EDTA congress in Budapest today, was to assess the potential of the DPP-4 inhibitor linagliptin (LINA), an oral diabetes drug, to reduce the burden of CKD and cardiac complications as secondary diseases in people with diabetes. Only a few weeks ago it had been shown that SGLT2 inhibitors, another class of diabetes drugs, could slow CKD progression in this patient group.

Dipeptidyl peptidase-4 (DPP-4) inhibitors are usually prescribed for patients with type 2 diabetes as second or third line drugs, when there is not sufficient treatment response to more widely used drugs like metformin. DPP-4 inhibitors block the enzyme DPP-4, which destroys incretins. Incretins stimulate the production of insulin and, thus, the blood sugar level decreases with the medication.

“But do DPP-4 inhibitors have any beneficial renal and cardiovascular effects? Can they prevent these secondary diseases of diabetes? This is what we wanted to find out in our trial,” explains lead investigator Professor Dr Christoph Wanner. The multicenter, randomized, double-blind CARMELINA trial compared LINA 5 mg vs placebo, added to standard of care, in people with type 2 diabetes and CV and/or kidney disease. The study assessed the cardio-renal disease burden and effects of the medication on CV, eGFR and albuminuria outcomes in participants with or without nephrotic-range proteinuria (defined as UACR ≥2200 mg/g at baseline).

It showed that 646 of the 6979 randomized participants had nephrotic-range proteinuria and, thus, suffered from renal disease. They were at high risk of CV events and had poor kidney outcomes; a 3-fold greater decline in eGFR was seen in those with nephrotic-range proteinuria at baseline.

The difference in HbA1c over the full trial duration favoured LINA (-0.36%). This did not differ between patients who had nephrotic-range proteinuria at baseline and those who had not. A larger proportion of patients who had received LINA vs placebo regressed to normoalbuminuria or had a reduction of urine albumin-to-creatinine ratio of ≥50% from baseline – regardless of nephrotic-range proteinuria status. However, loss in eGFR over time was not different between the groups (-6.51/year vs placebo -7.07/year), and the medication did not affect the risk for so called 3-point major adverse cardiovascular events (HR.1.02 [95% CI, 0.89, 1.17]), CV mortality (0.96 [0.81, 1.14]), or all-cause hospitalization (0.93 [0.85, 1.00]), in people with or without nephrotic-range proteinuria. 

“Linagliptin is effective in lowering HbA1c and albuminuria, but this did not translate into a better renal and cardiac outcome. It controlled the diabetes and it could halt albuminuria, but it had no additional clinical benefits. But the study clearly showed that there is a group of patients with diabetes who clearly are in need of outcome-enhancing therapies, because their prognosis is rather poor. Nephrotic-range proteinuria might be a good marker to stratify these patients. I would advise to treat these patients with SGLT2 inhibitors instead, or a combination of SGLT2 inhibitor and DPP-4 inhibitor. Apart from diabetes control, SGLT2 inhibitors have shown to be effective in renal and cardiovascular risk reduction [2]”, concluded lead investigator Professor Wanner.

References:
[1] Wanner C et al. Effects on kidney outcomes in patients with nephrotic range proteinuria: Insights from CARMELINA. LBCT Abstract ERA-EDTA Congress 2019, Budapest
[2] Perkovic V et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal 2019; 15 Apr. [epub ahead of print]; DOI: 10.1056/NEJMoa1811744

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Acute and Advanced Heart Failure

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

+ 3 more

Allergic Rhinitis

Allergic Rhinitis

Allergic rhinitis causes great strain on the workforce. Help to reduce sick days and improve productivity with appropriate treatment options.

+ 4 more

Atopic Dermatitis

Atopic Dermatitis

The Atopic Dermatitis Knowledge Centre is an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.

Load more

Related Content